ERBB2 and breast carcinoma: Jagosky and Liu [6,7] have recently reviewed several studies that support the substantial improvement in the outcome of HER2+ breast cancer patients with combined therapy of pertuzumab and trastuzumab [8,9,10,11,12,13,14,15,16,17].